Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte announced new data from a significant study involving over 10,000 men, highlighting the clinical utility of the Decipher Prostate genomic classifier. The findings suggest that Decipher tests can effectively guide prostate cancer treatment decisions, leading to improved patient care. Results indicate that men with low-risk scores are more likely to choose active surveillance, whereas those with higher-risk scores tend to opt for radical prostatectomy. This collaboration aims to enhance data for oncology researchers through the National Cancer Institute's SEER program.
Veracyte, Inc. (Nasdaq: VCYT) announced data from a clinical study showcasing the Immunoscore Immune Checkpoint (IC) assay's ability to predict which patients with metastatic non-small cell lung cancer (NSCLC) may benefit from immune checkpoint inhibitors (ICIs). Presented at the ASCO Annual Meeting on June 6, the study involved 265 patients, revealing that 100% of those with a high-risk score relapsed within 18 months, while a significant proportion of low-risk patients did not relapse for at least 36 months. The findings aim to enhance patient selection in clinical trials and optimize treatment approaches.
Veracyte (Nasdaq: VCYT) has announced CEO Marc Stapley and CFO Rebecca Chambers will present at the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 10:40 a.m. PT, and at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022, at 2:40 p.m. PT. Live audio webcasts will be accessible on Veracyte's website, with replays available for 90 days post-event. Veracyte is a global diagnostics firm focused on improving patient care through advanced diagnostic tests that address prevalent cancers and reduce unnecessary procedures.
Veracyte, Inc. (NASDAQ: VCYT) has presented new data on its Percepta Nasal Swab test at the American Thoracic Society 2022 International Conference. The test accurately assesses lung cancer risk in current and former smokers with lung nodules, irrespective of their smoking history. The study involved 291 smokers and highlighted its 96% sensitivity and 94% specificity for identifying high-risk nodules. The data suggests potential for reducing unnecessary procedures and facilitating timely treatment for lung cancer patients. Veracyte aims to enhance clinical utility evidence for reimbursement.
Veracyte has received favorable recognition in a new clinical guideline from the American Urological Association and the American Society for Radiation Oncology for its Decipher Prostate genomic classifier. This updated guideline emphasizes the significance of genomic testing in guiding treatment for localized prostate cancer, citing comprehensive evidence from phase 3 randomized clinical trials. The Decipher Prostate test helps predict cancer outcomes and assists physicians in making informed treatment decisions, ultimately improving patient care.
Veracyte (Nasdaq: VCYT) announced the presentation of six abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. These abstracts highlight the company's genomic and immuno-oncology tests, showing their potential to enhance cancer treatment outcomes, particularly in identifying patients with non-small cell lung cancer who may benefit from immune checkpoint inhibitors. CEO Marc Stapley emphasized the importance of these findings in advancing personalized medicine.
Veracyte (Nasdaq: VCYT) announced significant findings from the PROCURE study, presented at the ESMO Breast Cancer 2022 event in Berlin. The study, which involved 133 oncologists across 11 European countries, reveals that gene expression profile (GEP) testing is crucial for guiding treatment in early-stage breast cancer patients. Key findings include 88% of oncologists valuing GEP results for chemotherapy decisions in node-negative cases, and 75% considering it important for patients with 1 to 3 positive lymph nodes. The data suggests that GEP tests are becoming standard care in Europe.
Veracyte reported impressive first quarter 2022 results, with total revenue soaring by 85% to $67.8 million. Testing revenue reached $56.0 million, a 69% increase driven by the Decipher urology portfolio. Net loss improved by 65% to $14.5 million, corresponding to a $0.20 loss per share, a 70% enhancement year-over-year. The company anticipates total revenue for 2022 to range between $265 million and $275 million, indicating 21% to 25% growth compared to 2021. Cash and cash equivalents stood at $163.6 million.
Veracyte, Inc. (Nasdaq: VCYT) highlights the clinical importance of its Envisia Genomic Classifier for diagnosing idiopathic pulmonary fibrosis (IPF) following an updated practice guideline published in the American Journal of Respiratory and Critical Care Medicine. The guideline emphasizes the test's ability to identify a genomic pattern associated with usual interstitial pneumonia (UIP) without invasive procedures. The Envisia classifier boasts a specificity of 92% and sensitivity of 68%. A significant number of guideline authors advocate for its adoption in clinical settings, which could enhance diagnostic confidence for healthcare professionals.
Veracyte, Inc. (Nasdaq: VCYT) announced that three abstracts showcasing new genomic data on prostate and bladder cancers will be presented at the American Urological Association Annual Meeting from May 13-16, 2022, in New Orleans. These findings are sourced from the Decipher GRID database, encompassing over 100,000 transcriptomes. The data aims to enhance personalized cancer therapies, emphasizing the database's significance for urologic oncology research globally.